A recent report published in the New England Journal of Medicine has shed light on a concerning trend – colorectal cancer is on the rise among U.S. adults under 55. This new data underscores the importance of early detection and screening for this potentially deadly disease.
In a glimmer of hope, a new blood test has shown promising results in detecting colorectal cancer. Developed by Guardant Health, the test has been able to correctly identify the disease in 83% of people at average risk and without symptoms. This accuracy rate is comparable to the currently used stool tests for early cancer detection.
CBS News chief medical correspondent Dr. Jon LaPook has praised the blood test as an attractive alternative to current screening options. However, it is important to note that the test is not yet FDA approved, and most insurers do not cover its cost, which is $895 in the U.S.
Colorectal cancer is already the third most common cancer diagnosed in the U.S., with an estimated 106,590 new cases expected in 2024. Despite this, only 50% to 60% of eligible individuals undergo colorectal cancer screening, highlighting the need for more convenient and accessible options.
Guardant Health conducted a multisite clinical trial involving nearly 8,000 people, comparing the Shield blood test to colonoscopy, which is the current gold standard for colorectal cancer screening. The study comes at a critical time when colon cancer rates are on the rise, particularly among younger age groups.
As research continues to provide new tools for early cancer detection, it is crucial for individuals to stay informed about their screening options and discuss them with their healthcare providers. Stay tuned for further updates on this groundbreaking development in the fight against colorectal cancer.
“Infuriatingly humble tv expert. Friendly student. Travel fanatic. Bacon fan. Unable to type with boxing gloves on.”